Drug intelligence / Profile preview

CT076

Development stage: Preclinical
Lead developer: Shenzhen Celconta Life Science
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

CT076 is a preclinical-stage chimeric antigen receptor T-cell (CAR-T) therapy candidate developed by Guangdong Celconta Biotechnology (XKDBio). The therapy is engineered using the company's proprietary Trans-CAR platform to target Claudin 18.2 (CLDN18.2), a tight junction protein that is frequently overexpressed in various solid tumors, particularly gastric, esophageal, and pancreatic cancers. The Trans-CAR platform is designed to optimize the safety and efficacy profile of the T-cell product, aiming to overcome common challenges in treating solid tumors with cell therapies. As of current reports, CT076 remains in the preclinical research phase.

Other names: CT076CT-076CT 076

Targets

CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on CT076.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CT076.

Explore the full profile